We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Dyne Therapeutics Inc. (NASDAQ:DYN) stands against other promising small-cap stocks.
Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks are currently facing a choppy market, but he also acknowledged that he anticipates a rally later in the year. Based on this sentiment, he advised clients on the importance of diversification within the S&P 500 and pointed to opportunities in international markets. We covered his stance in greater detail in one of our other articles, 10 Best Small-Cap Value Stocks to Buy Now. Here’s an excerpt from it:
“He noted that the Trump trade initially boosted small caps due to expectations of economic acceleration and lower interest rates, both of which are favorable for these companies. However, policy uncertainty and weaker-than-expected economic data have delayed their rally. Teeter believes that small caps will come into their own later in the year, but for now, they are facing a choppy market with significant rotation.”
However, later on March 26, Villere & Co. Portfolio Manager George Young joined ‘Market Domination Overtime’ on Yahoo Finance to discuss why investors should be looking at small-cap stocks. George Young stated that small caps currently appear cheap and have been underperforming relative to larger stocks. He highlighted that small-cap stocks have been inexpensive for a while. To support his stance, he pointed out that last year, the S&P 500 rose about 25%, while small-cap stocks increased by only 11%. He explained that this disparity suggests a regression to the mean at some point, which means that the valuation gap between small caps and large caps should eventually narrow. Young also noted a shift in market dynamics during Q1 of this year. While the S&P 500 was down ~2% then, the S&P 500 excluding the MAG7 stocks was actually up ~2%. He described this change as a relatively usual once, since stock market leadership often rotates between sectors and types of stocks. Young particularly favored the small-cap sector when questioned about long-term and steady investments.
Our Methodology
We sifted through the Finviz stock screener to compile a list of the top small-cap stocks that were trading between $300 million and $2 billion, and that had the highest upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey’s database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A lab technician working with chemicals and equipment to create a novel therapeutic drug.
Dyne Therapeutics Inc. (NASDAQ:DYN)
Market Capitalization as of April 23: $1.26 billion
Number of Hedge Fund Holders: 41
Average Upside Potential as of April 23: 351.88%
Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that operates as a biotechnology company that is advancing therapeutics for genetically driven muscle diseases in the US. It’s developing a portfolio of muscle disease therapeutics with the help of its FORCE platform that delivers disease-modifying therapeutics.
The company’s DYNE-251 program is a key focus for the company and targets individuals with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 51 skipping. Data from the ongoing Phase 1/2 DELIVER trial has shown near-full-length dystrophin expression. Patients treated with the selected registrational dose of 20 mg/kg every 4 weeks showed a mean absolute dystrophin expression of 8.72% of normal (adjusted for muscle content) at the 6-month time point.
The DELIVER Registrational Expansion Cohort of 32 patients is now fully enrolled, with data expected in late 2025. Dyne anticipates a potential BLA submission for US accelerated approval for DYNE-251 in early 2026, based on dystrophin expression as a surrogate biomarker. The company believes that if approved, DYNE-251 has the potential for rapid adoption in the DMD community. BMO Capital Markets initiated coverage on Dyne on March 12 with an Outperform rating and a $50 price target.
Overall, DYN ranks 1st on our list of the most promising small-cap stocks according to analysts. While we acknowledge the growth potential of DYN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than DYN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
